Taniguchi M, Miller J F
J Exp Med. 1978 Aug 1;148(2):373-82. doi: 10.1084/jem.148.2.373.
A cell fusion technique was used to produce hybridomas between the T lymphoma cell line, EL-4, derived from C57BL (H-2(b)), and an enriched population of human gamma globulin (HGG)-specific suppressor T cells prepared from the spleens of HGG-tolerant CBA mice (H-2(k)). Membrane fluorescence analysis of the hybridoma cells within 6 wk of cell fusion revealed expression of H-2(k) and I-J(k) gene products as well as H-2(b) antigens. Sonicates prepared from hybridomas which contained I-J(k) cells were tested for suppressive activity in vivo in irradiated mice given HGG-primed cells, dinitrophenyl (DNP)-primed cells, HGG-DNP, and horse erythrocytes. Among 18 such hybridoma lines, 6 showed specific suppressive activity, 5 nonspecific suppression, and 7 no suppression. Most lines progressively lost, with time, those properties derived from the normal parent cell. By about 3 mo after fusion few cells expressed CBA markers and only one cell line (number 77) retained some specific suppressive activity. In parallel with the losses was an alteration in chromosome number from near-tetraploid, soon after cell fusion, to near- diploid. Preliminary results with the T lymphoma-sensitive hypoxanthine aminopterin thymidine cell line, L5178, indicate retention of the expression of surface markers derived from the normal parent for 18 wk after hybidization. This suggests that T lymphoma cell lines may have to be screened for their capacity to produce hybridomas with stable properties.
采用细胞融合技术,使源自C57BL(H-2(b))的T淋巴瘤细胞系EL-4与从耐受人γ球蛋白(HGG)的CBA小鼠(H-2(k))脾脏制备的富含HGG特异性抑制性T细胞群体产生杂交瘤。细胞融合后6周内对杂交瘤细胞进行膜荧光分析,结果显示其表达H-2(k)和I-J(k)基因产物以及H-2(b)抗原。对含有I-J(k)细胞的杂交瘤制备的超声裂解物,在给予HGG致敏细胞、二硝基苯基(DNP)致敏细胞、HGG-DNP和马红细胞的受辐照小鼠体内检测其抑制活性。在18个这样的杂交瘤细胞系中,6个表现出特异性抑制活性,5个表现出非特异性抑制,7个无抑制作用。大多数细胞系随着时间的推移逐渐丧失了源自正常亲本细胞的那些特性。融合后约3个月,很少有细胞表达CBA标记,只有一个细胞系(77号)保留了一些特异性抑制活性。与这些特性丧失同时发生的是,染色体数目从细胞融合后不久的近四倍体变为近二倍体。对T淋巴瘤敏感的次黄嘌呤氨基蝶呤胸腺嘧啶核苷细胞系L5178的初步结果表明,杂交后18周仍保留源自正常亲本的表面标记的表达。这表明可能必须筛选T淋巴瘤细胞系产生具有稳定特性杂交瘤的能力。